18th Scientific meeting of the International Society of Hypertension.
Danser
A H
AH
Department of Pharmacology, Erasmus University, Rotterdam, The Netherlands.
Schuijt
M P
MP
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002641:Chicago; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics; D007093:Imidazoles / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D000068557:Olmesartan Medoxomil; D011480:Protease Inhibitors / Q000627:therapeutic use*; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D012955:Societies, Medical; D013777:Tetrazoles / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors; D007093:Imidazoles; D011480:Protease Inhibitors; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil; D019001:Nitric Oxide Synthase